A 2-Stage, Phase I/II, Active-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis MRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GBP 560 (Primary)
Indications Japanese encephalitis
Focus Adverse reactions; Pharmacodynamics
Sponsors SK Bioscience

Most Recent Events

12 Dec 2024 According to the SK Bioscience Media Release, the company has received approval from the Human Research Ethics Committee (HREC) in Australia for the clinical trial protocols of a Phase 1/2 trial for its mRNA-based Japanese encephalitis vaccine candidate, GBP560. The company anticipates initiating the clinical trial in Australia by February 2025, with interim results expected by 2026.
15 Nov 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight